Position in ADCT
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$20,990,373
+$1,662,095 QoQ
Shares Held
5,597,433
+2.2% QoQ
Ownership
4.40%
of shares outstanding
% of Portfolio
1.32%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2022
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ADCT Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Nantahala Capital Management, LLC holds $159,502,303 across 10 Drug Manufacturers - Specialty & Generic names. ADCT ranks #4 (13.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AMRX |
Amneal Pharmaceuticals, Inc.
|
2,844,108 | $35,352,262 | |
| 2 | ETON |
Eton Pharmaceuticals, Inc.
|
1,175,951 | $29,022,470 | |
| 3 | EOLS |
Evolus, Inc.
|
6,376,857 | $26,208,882 | |
| 4 | ADCT |
ADC Therapeutics SA
This page
|
5,597,433 | $20,990,373 | |
| 5 | BCRX |
Biocryst Pharmaceuticals Inc
|
1,987,397 | $18,920,019 | |
| 6 | ASRT |
Assertio Holdings, Inc.
|
692,335 | $13,195,905 | |
| 7 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
535,684 | $7,446,007 | |
| 8 | AYTU |
Aytu Biopharma, Inc
|
1,086,812 | $2,966,996 |
All Filings in ADCT
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $20,990,373 | 5,597,433 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $19,328,278 | 5,475,433 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $9,065,156 | 2,266,289 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $6,073,654 | 2,266,289 | Shares | Sole | 2025-08-14 | |
| 2023-09-30 | $230,674 | 257,162 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $1,806,000 | 840,000 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $1,638,000 | 840,000 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $934,233 | 243,290 | Shares | Sole | 2023-02-14 | |
| No filing history on record for this holder in this stock. | ||||||